patient with stage G4/A3 CKD should receive the 13-valent pneumococcal conjugate vaccine (PCV-13) 1 or more years after the 23-valent pneumococcal polysaccharide vaccine (PPSV-23). A second dose of PPSV-23 should be administered [...] years after the first dose.
Answer
5 or more
Question
patient with stage G4/A3 CKD should receive the 13-valent pneumococcal conjugate vaccine (PCV-13) 1 or more years after the 23-valent pneumococcal polysaccharide vaccine (PPSV-23). A second dose of PPSV-23 should be administered [...] years after the first dose.
Answer
?
Question
patient with stage G4/A3 CKD should receive the 13-valent pneumococcal conjugate vaccine (PCV-13) 1 or more years after the 23-valent pneumococcal polysaccharide vaccine (PPSV-23). A second dose of PPSV-23 should be administered [...] years after the first dose.
Answer
5 or more
If you want to change selection, open original toplevel document below and click on "Move attachment"
Parent (intermediate) annotation
Open it pan>patient with stage G4/A3 CKD should receive the 13-valent pneumococcal conjugate vaccine (PCV-13) 1 or more years after the 23-valent pneumococcal polysaccharide vaccine (PPSV-23). A second dose of PPSV-23 should be administered 5 or more years after the first dose.<span><body><html>
Original toplevel document (pdf)
owner: ELBOMBARDO - (no access) - MKSAP_17.pdf, p3429
Summary
status
not learned
measured difficulty
37% [default]
last interval [days]
repetition number in this series
0
memorised on
scheduled repetition
scheduled repetition interval
last repetition or drill
Details
No repetitions
Discussion
Do you want to join discussion? Click here to log in or create user.